Clinical Trial Update: Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of tamoxifen and pegylated liposomal doxorubicin for metastatic or locally advanced triple-negative breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Status: RECRUITING